Quantbot Technologies LP Makes New $878,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Quantbot Technologies LP bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,546 shares of the medical research company's stock, valued at approximately $878,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Blue Trust Inc. boosted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares during the period. Versant Capital Management Inc boosted its position in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its stake in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. grew its stake in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. Finally, True Wealth Design LLC acquired a new position in shares of Natera in the 3rd quarter valued at about $57,000. 99.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Solomon Moshkevich sold 1,026 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.04, for a total value of $149,837.04. Following the sale, the insider now owns 144,782 shares of the company's stock, valued at $21,143,963.28. The trade was a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider John Fesko sold 663 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 306,797 shares of company stock worth $48,940,883. 7.60% of the stock is currently owned by company insiders.

Remove Ads

Natera Stock Performance

Shares of Natera stock traded down $4.36 during midday trading on Friday, hitting $143.94. The company had a trading volume of 1,258,459 shares, compared to its average volume of 1,364,577. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The business's 50 day simple moving average is $159.60 and its two-hundred day simple moving average is $151.13. The stock has a market cap of $19.46 billion, a PE ratio of -81.78 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on NTRA shares. Piper Sandler boosted their price target on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Morgan Stanley raised their price target on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. boosted their price target on Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. Barclays began coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price for the company. Finally, Royal Bank of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Natera has an average rating of "Moderate Buy" and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.